Shaw Lindsey N, Golonka Ewa, Szmyd Grzegorz, Foster Simon J, Travis James, Potempa Jan
Department of Biochemistry and Molecular Biology, University of Georgia, Life Sciences Bldg., Athens, GA 30602, USA.
J Bacteriol. 2005 Mar;187(5):1751-62. doi: 10.1128/JB.187.5.1751-1762.2005.
The cytoplasmic protein SspC of Staphylococcus aureus, referred to as staphostatin B, is a very specific, tightly binding inhibitor of the secreted protease staphopain B (SspB). SspC is hypothesized to protect intracellular proteins against proteolytic damage by prematurely folded and activated staphopain B (M. Rzychon, A. Sabat, K. Kosowska, J. Potempa, and A. Dubin, Mol. Microbiol. 49:1051-1066, 2003). Here we provide evidence that elimination of intracellular staphopain B activity is indeed the function of SspC. An isogenic sspC mutant of S. aureus 8325-4 exhibits a wide range of striking pleiotropic alterations in phenotype, which distinguish it from the parent. These changes include a defect in growth, a less structured peptidoglycan layer within the cell envelope, severely decreased autolytic activity, resistance to lysis by S. aureus phages, extensively diminished sensitivity to lysis by lysostaphin, the ability to form a biofilm, and a total lack of extracellular proteins secreted into the growth media. The same phenotype was also engineered by introduction of sspB into an 8325-4 sspBC mutant. In contrast, sspC inactivation in the SH1000 strain did not yield any significant changes in the mutant phenotype, apparently due to strongly reduced expression of sspB in the sigma B-positive background. The exact pathway by which these diverse aberrations are exerted in 8325-4 is unknown, but it is apparent that a very small amount of staphopain B (less than 20 ng per 200 microg of cell proteins) is sufficient to bring about these widespread changes. It is proposed that the effects observed are modulated through the proteolytic degradation of several cytoplasmic proteins within cells lacking the inhibitor. Seemingly, some of these proteins may play a role in protein secretion; hence, their proteolytic inactivation by SspB has pleiotropic effects on the SspC-deficient mutant.
金黄色葡萄球菌的细胞质蛋白SspC,被称为葡萄抑素B,是分泌型蛋白酶葡萄蛋白酶B(SspB)的一种非常特异且紧密结合的抑制剂。据推测,SspC可保护细胞内蛋白质免受过早折叠和激活的葡萄蛋白酶B的蛋白水解损伤(M. Rzychon、A. Sabat、K. Kosowska、J. Potempa和A. Dubin,《分子微生物学》49:1051 - 1066,2003年)。在此,我们提供证据表明消除细胞内葡萄蛋白酶B活性确实是SspC的功能。金黄色葡萄球菌8325 - 4的同基因sspC突变体在表型上表现出广泛且显著的多效性改变,使其与亲本菌株有所区别。这些变化包括生长缺陷、细胞壁内肽聚糖层结构较差、自溶活性严重降低、对金黄色葡萄球菌噬菌体裂解的抗性、对溶葡萄球菌素裂解的敏感性大幅降低、形成生物膜的能力以及完全缺乏分泌到生长培养基中的细胞外蛋白质。将sspB导入8325 - 4 sspBC突变体也产生了相同的表型。相比之下,SH1000菌株中的sspC失活并未使突变体表型产生任何显著变化,显然这是由于在σB阳性背景下sspB的表达大幅降低所致。8325 - 4菌株中这些多样异常表现所涉及的确切途径尚不清楚,但很明显,极少量的葡萄蛋白酶B(每200微克细胞蛋白中少于20纳克)就足以引发这些广泛的变化。据推测,所观察到的效应是通过对缺乏抑制剂的细胞内几种细胞质蛋白的蛋白水解降解来调节的。显然,其中一些蛋白质可能在蛋白质分泌中起作用;因此,它们被SspB进行蛋白水解失活会对缺乏SspC的突变体产生多效性影响。